Cargando…

Theragnostic chromosomal rearrangements in treatment‐naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound

A crucial mutational mechanism in malignancy is structural variation, in which chromosomal rearrangements alter gene functions that drive cancer progression. Herein, the presence and pattern of structural variations were investigated in twelve prospectively acquired treatment‐naïve pancreatic cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Stephen J., Levy, Michael J., Smadbeck, James B., Karagouga, Giannoula, McCune, Alexa F., Harris, Faye R., Udell, Julia B., Johnson, Sarah H., Kerr, Sarah E., Cheville, John C., Kipp, Benjamin R., Vasmatzis, George, Gleeson, Ferga C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051743/
https://www.ncbi.nlm.nih.gov/pubmed/33704908
http://dx.doi.org/10.1111/jcmm.16381
_version_ 1783679790077706240
author Murphy, Stephen J.
Levy, Michael J.
Smadbeck, James B.
Karagouga, Giannoula
McCune, Alexa F.
Harris, Faye R.
Udell, Julia B.
Johnson, Sarah H.
Kerr, Sarah E.
Cheville, John C.
Kipp, Benjamin R.
Vasmatzis, George
Gleeson, Ferga C.
author_facet Murphy, Stephen J.
Levy, Michael J.
Smadbeck, James B.
Karagouga, Giannoula
McCune, Alexa F.
Harris, Faye R.
Udell, Julia B.
Johnson, Sarah H.
Kerr, Sarah E.
Cheville, John C.
Kipp, Benjamin R.
Vasmatzis, George
Gleeson, Ferga C.
author_sort Murphy, Stephen J.
collection PubMed
description A crucial mutational mechanism in malignancy is structural variation, in which chromosomal rearrangements alter gene functions that drive cancer progression. Herein, the presence and pattern of structural variations were investigated in twelve prospectively acquired treatment‐naïve pancreatic cancers specimens obtained via endoscopic ultrasound (EUS). In many patients, this diagnostic biopsy procedure and specimen is the only opportunity to identify somatic clinically relevant actionable alterations that may impact their care and outcome. Specialized mate pair sequencing (MPseq) provided genome‐wide structural variance analysis (SVA) with a view to identifying prognostic markers and possible therapeutic targets. MPseq was successfully performed on all specimens, identifying highly rearranged genomes with complete SVA on all specimens with > 20% tumour content. SVA identified chimeric fusion proteins and potentially immunogenic readthrough transcripts, change of function truncations, gains and losses of key genes linked to tumour progression. Complex localized rearrangements, termed chromoanagenesis, with broad pattern heterogeneity were observed in 10 (83%) specimens, impacting multiple genes with diverse cellular functions that could influence theragnostic evaluation and responsiveness to immunotherapy regimens. This study indicates that genome‐wide MPseq can be successfully performed on very limited clinically EUS obtained specimens for chromosomal rearrangement detection and potential theragnostic targets.
format Online
Article
Text
id pubmed-8051743
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80517432021-04-21 Theragnostic chromosomal rearrangements in treatment‐naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound Murphy, Stephen J. Levy, Michael J. Smadbeck, James B. Karagouga, Giannoula McCune, Alexa F. Harris, Faye R. Udell, Julia B. Johnson, Sarah H. Kerr, Sarah E. Cheville, John C. Kipp, Benjamin R. Vasmatzis, George Gleeson, Ferga C. J Cell Mol Med Original Articles A crucial mutational mechanism in malignancy is structural variation, in which chromosomal rearrangements alter gene functions that drive cancer progression. Herein, the presence and pattern of structural variations were investigated in twelve prospectively acquired treatment‐naïve pancreatic cancers specimens obtained via endoscopic ultrasound (EUS). In many patients, this diagnostic biopsy procedure and specimen is the only opportunity to identify somatic clinically relevant actionable alterations that may impact their care and outcome. Specialized mate pair sequencing (MPseq) provided genome‐wide structural variance analysis (SVA) with a view to identifying prognostic markers and possible therapeutic targets. MPseq was successfully performed on all specimens, identifying highly rearranged genomes with complete SVA on all specimens with > 20% tumour content. SVA identified chimeric fusion proteins and potentially immunogenic readthrough transcripts, change of function truncations, gains and losses of key genes linked to tumour progression. Complex localized rearrangements, termed chromoanagenesis, with broad pattern heterogeneity were observed in 10 (83%) specimens, impacting multiple genes with diverse cellular functions that could influence theragnostic evaluation and responsiveness to immunotherapy regimens. This study indicates that genome‐wide MPseq can be successfully performed on very limited clinically EUS obtained specimens for chromosomal rearrangement detection and potential theragnostic targets. John Wiley and Sons Inc. 2021-03-11 2021-04 /pmc/articles/PMC8051743/ /pubmed/33704908 http://dx.doi.org/10.1111/jcmm.16381 Text en © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Murphy, Stephen J.
Levy, Michael J.
Smadbeck, James B.
Karagouga, Giannoula
McCune, Alexa F.
Harris, Faye R.
Udell, Julia B.
Johnson, Sarah H.
Kerr, Sarah E.
Cheville, John C.
Kipp, Benjamin R.
Vasmatzis, George
Gleeson, Ferga C.
Theragnostic chromosomal rearrangements in treatment‐naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound
title Theragnostic chromosomal rearrangements in treatment‐naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound
title_full Theragnostic chromosomal rearrangements in treatment‐naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound
title_fullStr Theragnostic chromosomal rearrangements in treatment‐naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound
title_full_unstemmed Theragnostic chromosomal rearrangements in treatment‐naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound
title_short Theragnostic chromosomal rearrangements in treatment‐naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound
title_sort theragnostic chromosomal rearrangements in treatment‐naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051743/
https://www.ncbi.nlm.nih.gov/pubmed/33704908
http://dx.doi.org/10.1111/jcmm.16381
work_keys_str_mv AT murphystephenj theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT levymichaelj theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT smadbeckjamesb theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT karagougagiannoula theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT mccunealexaf theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT harrisfayer theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT udelljuliab theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT johnsonsarahh theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT kerrsarahe theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT chevillejohnc theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT kippbenjaminr theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT vasmatzisgeorge theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound
AT gleesonfergac theragnosticchromosomalrearrangementsintreatmentnaivepancreaticductaladenocarcinomasobtainedviaendoscopicultrasound